Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29757749 | 0.82 | TSHR (0.45) | ALDH1A1CYP3A4MAPTTSHRTDP1 | |
| SCHEMBL56541 | 0.82 | TSHR (0.45) | ALDH1A1CYP3A4MAPTTSHRTDP1 | |
| SCHEMBL3790793 | 0.81 | ALDH1A1 (0.39) | ALDH1A1CYP3A4DHFRMAPTTSHR | |
| SCHEMBL30987781 | 0.81 | CYP3A4 (0.44) | ALDH1A1CYP3A4DHFRMAPTTSHR | |
| SCHEMBL30987771 | 0.81 | ALDH1A1 (0.44) | ALDH1A1CYP3A4DHFRMAPTTSHR | |
| SCHEMBL23234456 | 0.81 | ALDH1A1 (0.44) | ALDH1A1CYP3A4DHFRMAPTTSHR | |
| SCHEMBL13019612 | 0.81 | ALDH1A1 (0.39) | ALDH1A1CYP3A4DHFRMAPTTSHR | |
| SCHEMBL2975188 | 0.81 | CYP3A4 (0.44) | ALDH1A1CYP3A4DHFRMAPTTSHR | |
| SCHEMBL8483314 | 0.81 | ALDH1A1 (0.42) | ALDH1A1CYP3A4DHFRMAPTTSHR | |
| SCHEMBL12477761 | 0.81 | ALDH1A1 (0.43) | ALDH1A1CYP3A4DHFRMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4638420-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | Exelixis, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024137671-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | EXELIXIS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240101558-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2024-03-28 | — | — | US | disclosed |
| US-11851429-B2 | AMPK activators | KALLYOPE, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11708376-B2 | Substituted imidazo[4,5-b]pyridines, imidazo[4,5-b]pyrazines, and oxazolo[4,5- b]pyrazines as mitochondrial uncouplers | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708376-B2 | Substituted imidazo[4,5-b]pyridines, imidazo[4,5-b]pyrazines, and oxazolo[4,5- b]pyrazines as mitochondrial uncouplers | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708376-B2 | Substituted imidazo[4,5-b]pyridines, imidazo[4,5-b]pyrazines, and oxazolo[4,5- b]pyrazines as mitochondrial uncouplers | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| CN-116390925-A | AMPK activator | 卡尔优普公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-116323608-A | AMPK activator | 卡尔优普公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20130184240-A1 | HETERO RING-FUSED IMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | SHIONOGI & CO., LTD. (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2614052-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | Bristol-Myers Squibb Company (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20130123237-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8362004-B2 | Piperazine analogs as broad-spectrum influenza antivirals | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362004-B2 | Piperazine analogs as broad-spectrum influenza antivirals | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| WO-2012116145-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012033736-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
| US-4087432-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | ZC3HAV1, ZC3HAV1L, HCRTR1 | ALDH1A1 728/4885CYP3A4 367/4885DHFR 2114/4885 |
| US-20130184240-A1 | HETERO RING-FUSED IMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | PRKAA1, PRKAA2, PRKAG1 | ALDH1A1 3389/4885CYP3A4 1763/4885DHFR 3649/4885 |
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | ALDH1A1 4339/4885CYP3A4 3939/4885DHFR 4719/4885 |
| US-11708376-B2 | Substituted imidazo[4,5-b]pyridines, imidazo[4,5-b]pyrazines, and oxazolo[4,5- b]pyrazines as mitochondrial uncouplers | NDUFAF1, NDUFAB1, GLS2 | ALDH1A1 471/4885CYP3A4 612/4885DHFR 2375/4885 |
| US-20130123237-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAB2, PRKAG1 | ALDH1A1 2545/4885CYP3A4 3085/4885DHFR 1585/4885 |
| US-11851429-B2 | AMPK activators | PRKAG1, PRKAG2, PRKAG3 | ALDH1A1 2034/4885CYP3A4 4583/4885DHFR 3723/4885 |
| US-20240101558-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAG3 | ALDH1A1 2034/4885CYP3A4 4583/4885DHFR 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.